Please select the option that best describes you:
What are your top takeaways from ASCO GU 2024?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
Answer from: Medical Oncologist at Academic Institution
Prostate. BRCAAway. This small but important phase 2 randomized multicenter trial of HRRm mCRPC in the first line setting demonstrated the clear synergy in delaying progression or death and inducing better response between abiraterone and olaparib as compared to either abi or olaparib monothe...
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
GETUG 18 is an RCT for high-risk PCa receiving LT-ADT for 3 years and 70 Gy vs 80 Gy with conventional fractionation. All patients had nodal RT (unless had PLND). The 10-year PFS was 83.6% vs 72.2%. The 10-year OS was 77% vs 65.9%. There was no difference in morbidity between the two arms but appear...
Answer from: Medical Oncologist at Academic Institution
AMBASSADOR Alliance A031501 trial provides additional evidence to support a DFS benefit with adjuvant immune checkpoint inhibition (pembrolizumab) in patients with muscle-invasive and locally advanced urothelial carcinoma. NCT03244384
Although CONTACT-02 demonstrated a PFS benefit for caboza...
Answer from: Medical Oncologist at Academic Institution
Results of the AMBASSADOR study for adjuvant pembrolizumab therapy for urothelial cancer
Further analysis of the EMBARK study
OS results from KEYNOTE-564 of adjuvant pembrolizumab in clear cell RCC